Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Charikleia Kelaidi,S. Park,Rosa Sapena,Odile Beyne-Rauzy,Valérie Coiteux,N. Vey,A. Stamatoullas,Bachra Choufi,Jacques Delaunay,M-P Gourin,Stéphane Cheze,Christophe Ravoet,A. Ferrant,Martine Escoffre-Barbe,L. Aljassem,E. Raffoux,Raphael Itzykson,L. Ades,Francois Dreyfus,P. Fenaux

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

2013

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Keywords:

Cancer research
Refractory
Oncology
Erythropoiesis
Lower risk
5q Deletion
Myelodysplastic syndromes
Internal medicine
Surgery
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations